Under a tenth of individuals eligible to benefit from obesity jabs including Wegovy can access them, states the WHO as it releases its initial guidance on the medications.
Given more than one billion individuals worldwide currently obese, it is calling for broader and more equitable access to GLP-1 medication.
According to projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our latest guidelines acknowledges that obesity is a lifelong illness that can be treated with thorough and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are significant hurdles to broad access to the injections that can assist patients in reducing substantial body mass, says the organization.
Weight-Loss Drug Shortage
Even under the present best projected case, the supply of these medications could only cover about 100 million people – less than 10% of eligible patients, per the WHO.
The guideline encourages governments and firms to widen access, by strategies such as licensing agreements.
The intellectual property rights on a key compound – the core component of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026.
The Way Weight-Loss Injections Function
The injections mimick a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so people reduce food intake.
People usually begin shedding pounds in the initial weeks of starting on the regular doses.
Evidence suggests patients may put most of the weight back on after a year of halting the treatment, when their usual hunger return.
To be above a healthy weight increases your likelihood for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight affects individuals in every country and was linked to millions of fatalities worldwide in 2024, according to the health agency.
